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Background: Major depression is associated with higher plasma levels of positive acute-phase proteins, as well as
with lower plasma levels of negative acute-phase proteins. The aim of this study is to examine the levels of acute-
phase response proteins and whether these levels are influenced by reproductive hormones and antidepressant
medication in the perimenopausal depression.
Methods: Sixty-five women (age range: 40–58 years old) participated in this study. All women were in the
perimenopausal phase. The diagnosis of depression was made through a psychiatric interview and with the aid of
Hamilton Depression Rating Scale 17 (HAM-D 17). The acute-phase response proteins, such as haptoglobin (HP),
transferrine (TRf), α1-antitrypsin, complement protein 3 (C3), complement protein 4 (C4) and C-reactive protein
(CRP) and the reproductive hormones, for example follicle-stimulating hormone (FSH), luteinizing hormone (LH) and
estradiol (E2), were analyzed using standard laboratory methods. Pearson’s correlations were applied to evaluate the
relationship between acute-phase proteins and hormones.
Results: Perimenopausal women were divided into three groups. The first group consisted of normal controls, the
second one involved depressed perimenopausal women, who were taking selective serotonin reuptake inhibitors
(SSRIs), and the third one included depressed women that were not treated with SSRIs. Depressed women in
perimenopause, when being compared to non-depressed women, did not differ as to serum levels of acute-phase
proteins. There was a positive correlation between HP and E2 in depressed perimenopausal women, who were not
taking SSRIs.
Conclusions: The lack of association between acute-phase proteins and depressive mood mentioned in this study
does not support previous findings in patients with major depression. This negative finding in perimenopausal
depression indicates either the absence or a more complex nature of the interactions between acute-phase proteins,
low-grade inflammation and depression. The hormonal profile of women is a part of this complexity, because it seems
that in perimenopause the hormonal changes are accompanied by changes of acute-phase response proteins.
Particularly, in perimenopausal depression, there is an interaction between HP and E2. Therefore, it seems that
perimenopause is a period of a woman’s life during which hormonal, immune and metabolic changes occur and
interact with each other making women vulnerable to depression.
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Changes in the immune system of patients suffering
from major depression have been reported extensively in
the literature. Several studies provided evidence for in-
flammatory reactions in major depression (MD) [1-3].
Due to its crucial role in acute inflammatory reactions of
the body, great attention has been paid to the monocyte-
macrophage system.
During immune responses, monocytes (similarly to
macrophages) do not just exert local effects. Cytokines,
produced by monocytes, exert far-reaching effects on
the body. They increase body temperature and stimulate
hepatocytes so that acute-phase proteins are produced
(e.g. haptoglobin, C-reactive protein, α1-macroglobulin).
These proteins activate the complement system and
opsonize exogenous organisms, such as bacteria.
C-reactive protein (CRP) is one of the most frequently
measured acute-phase proteins in clinical medicine. Sev-
eral studies reported increased serum levels of CRP in
patients suffering from MD [4-11], while in other investiga-
tions, no differences in CRP serum levels between patients
with MD and healthy controls could be found [12-14].
Haptoglobin (HP) is the most frequently studied acute-
phase protein in MD, which has provided the most con-
sistent results. Several groups demonstrated increased HP
serum levels in MD [8,13-21].
Another acute-phase protein α2-macroglobulin (A2M)
was found to be significantly higher in patients with
acute MD after 6 weeks of clinical treatment compared
to healthy controls [8]. Maes et al. [14] reported normal
A2M in MD with a trend towards lower levels in
melancholia.
Obviously, there is a lack of consistency in the re-
sponses of the investigated immune parameters. One
reason for this might be that the diagnostic group of
MD, classified according to DSM-IV-TR criteria, is simply
much heterogeneous. Few researchers have attempted to
deal with this problem. Some others have tried to deter-
mine associations between immune parameters and sever-
ity or type of depression [13,18,22-24], or they have
sought and found correlations between psychopatho-
logical features and immune function [25]. Another ap-
proach has been the study of immunological changes at
different stages during the course of the disease [8,26,27].
The DSM-IV-TR classification category of MD covers
different kinds of depression but not all of them. The
subtypes of depression do not just differ quantitatively;
they also differ as far as the quality of the symptoms is
concerned [28].
Perimenopausal depression is a type of depression that
is not included in the DSM-IV-TR. Throughout most of
their lives, women are at greater risk of depression com-
pared to men. The perimenopause and early postmeno-
pausal period have been considered as a “window ofvulnerability”, during which physical and emotional dis-
comforts emerge as well as hormonal changes can lead
to the appearance of depression. The mechanisms that
are responsible for the development of depression in
perimenopausal women remain unclear. Studies identi-
fied an increased risk of clinical depression, particularly
among women with a history of depression [29-32] Al-
though a history of depression continues to be the stron-
gest predictor of a depressive episode, several studies
identified depressed mood in perimenopausal women
with no history of depression and also identified associa-
tions between depression and changes in the hormonal
milieu [31-33].
Inflammation levels fluctuate throughout a woman’s
life according to hormonal changes that occur due to
the phase of menstrual cycle, the use of hormonal con-
traceptives, the menopause and the use of estrogens
[34-36], which might influence the relationship between
depression and inflammation.
The first aim of this study is to investigate whether
positive acute-phase proteins (haptoglobin, α1−antitryp-
sin and C-reactive protein) and proteins of the comple-
ment (C3 and C4) increase, while negative acute-phase
proteins, such as transferrin, decrease in perimenopausal
depression. The second aim is to examine whether re-
productive hormones have an impact on the levels of
acute-phase response proteins in perimenopausal de-
pression. Lastly, possible effects of SSRIs on acute-phase
response proteins levels are examined.Methods
Subjects
A total of 65 women that were recruited consecutively
as a case series from the Outpatient Clinics and the De-
partments of Obstetrics, Gynaecology and Psychiatry of
the University Hospital of Larissa, Greece, participated
in the study. Normal controls included women, who vis-
ited the outpatient department of Gynaecology, in order
to take a Pap test, as a routine examination. All partici-
pants were Caucasian and they were divided into two
groups. The first group consisted of perimenopausal
women suffering from depression (n = 39) and the second
one involved perimenopausal women without depression
(n = 26). All women were in the perimenopausal phase,
characterized by the presence of irregular cycles or amen-
orrhea for less than 12 months. The serum levels of follicle
stimulating hormone (FSH) were over 20 IU/l for each
participant in the study [37].
Furthermore, the exclusion criteria were the following:
the presence of bipolar disorder, other psychiatric dis-
eases (e.g. schizophrenia), diseases that can affect the
immune system or cause depression (e.g. rheumatoid
arthritis), the use of medications, except for SSRIs, recent
Table 2 Serum TRf, AAT, C3 and HP concentrations in 39
women with perimenopausal depression, compared to








(n = 39) (n = 26) t-test
TRf (mg/dl) 259.97 (47.54) 253.65 (45.52) 0,595 ns
AAT (mg/dl) 153.95 (23.93) 144.73 (23.55) 0,131 ns
C3 (mg/dl) 147.41 (44.62) 147.73 (33.21) 0,976 ns
HP (mg/dl) 142.66 (45.58) 143.91 (49.02) 0,917 ns
All results are expressed as mean (SD); ns, not significant.
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oral contraceptives and hormone replacement therapy.
19 out of 39 women with depression had a history of
depression and they were taking SSRIs, such as citalo-
pram, fluoxetine or sertraline alone. Each woman had
been taking SSRIs for more than a month without any
other psychotropic or non-psychotropic medication.
These women had experienced more than two episodes
of depression in the past and they were still depressed,
when enrolled into the study (17-item Hamilton Depres-
sion Rating Scale (HAM-D 17) score >10). Conse-
quently, this subgroup of depressed perimenopausal
women treated with SSRIs was classified as patients re-
sistant to this class of antidepressants and therefore still
depressed. The remaining 17 women had their first epi-
sode of depression during perimenopause and they had
never used psychotropic medications. Depression was
diagnosed through a psychiatric interview and the ad-
ministration of the HAM-D 17. A woman would have
been considered depressed, if she had scored over 10 on
the HAM-D 17 and had fulfilled the criteria of major de-
pression according to International Classification of Dis-
eases, tenth edition (ICD-10). If a woman had scored
less than or equal to 10 on the HAM-D 17, she would
have been considered normal.
Venous blood samples were collected from 8.00 a.m.
until 12.00 a.m. Samples were centrifuged at 3,500 rpm
for 5 minutes and aliquots of serum samples were stored
at −80°C until further use.
Informed consent for participation in this study was
obtained from each woman. The ethics committee of the
University Hospital of Larissa approved this study.
Measurement of inflammatory markers
CRP, HP, Tf, C3, C4 and AAT concentrations were deter-
mined by laser nephelometry (Nefelometer, BN II Sys-
tem, Dade Behring). All antisera, controls and standards











Age 50.10 ± 3.95 48.29 ± 10.95 0.94 (ns)a
Education (years) 8.22 ± 3.87 8.29 ± 3.93 0.94 (ns)a
Amenorrhea (months) 6.88 ± 4.62 7.10 ± 3.94 0.59 (ns)a
Married 36 (87.8%) 22 (91.7%) 0.37 (ns)b
Current smokers 15 (36.6%) 7 (29.2%) 0.6 (ns)b
Alcohol users 1 (0.02%) 0 (0%) 1 (ns)b
HAM-D 16.85 ± 5.02 5.68 ± 2.52 <0.0001a
aMann–Whitney; bChi-Square test; ns, not significant; HAM-D, Hamilton
Depression Rating Scale.Dade Behring. We used a single batch of antiserum for
each parameter and included appropriate controls in
each run.
Statistics
Data analysis was conducted using the commercially
available computer software SPSS V.15.0 (SPSS Inc.,
Chicago, IL, USA). The normality assumption was
checked using the Shapiro test. When departures from
normality were significant, non-parametric methods
were used. In this case, the differences in acute-phase re-
sponse protein concentrations between depressed and
non-depressed perimenopausal women were analysed
with the Mann–Whitney U test. On the contrary, when
the data followed the normal distribution, t-test was
used. Associations between continuous variables were
tested using Pearson’s or Spearman’s correlations. Linear
regression analyses were performed in order to find out
if age, profession, education, marriage, months of amen-
orrhoea, smoking and alcohol intake affected the levels
of acute-phase response proteins. A difference between
two groups was considered to be statistically significant,
when p < 0.05.
Results
The major characteristics of perimenopausal women,
with or without depression, are summarized in Table 1.
The two groups did not differ in terms of age, years of
education, months of amenorrhea, smoking habits, alco-
hol intake or marital status. As was expected, depressedTable 3 Serum C4 and CRP concentrations in 39 women
with perimenopausal depression, compared to those








(n = 39) (n = 26) Mann-Whitney
C4 (mg/dl) 32.80 (18.60-48.90) 29.20 (19.06-47.14) 0.445 ns
CRP (mg/dl) 0.20 (0.00-0.60) 0.10 (0.00-0.99) 0.603 ns
The results of C4 and CRP are expressed as medians (10-90%); ns, not significant.
Table 4 Serum TRf, AAT, C3 and HP concentrations in 39 women with perimenopausal depression, subdivided to those
receiving (n = 17) or not (n = 22) selective serotonin reuptake inhibitors (SSRIs) compared to those women without
perimenopausal depression (n = 26)
Perimenopausal with Women depression Perimenopausal women
without depression
P-value (ANOVA)
Not treated with SSRIs Treated with SSRIs
N = 22 N = 17 N = 26
TRf (mg/dl) 248.59 (43.35) 267.65 (45.38) 253.65 (45.52) 0.492 ns
AAT (mg/dl) 149.14 (24.03) 158.71 (25.33) 144.73 (23.55) 0.102 ns
C3 (mg/dl) 138.19 (50.10) 158.24 (35.39) 147.73 (33.21) 0.194 ns
HP (mg/dl) 145.14 (46.67) 142.12 (39.91) 143.91 (49.02) 0.918 ns
All results are expressed as mean (SD); ns, not significant.
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without depression (Table 1). Linear regression analyses
showed that the levels of CRP, AAT, HP and C4 were
not affected by age, professional, education, marriage,
months of amenorrhoea, smoking and alcohol intake.
On the contrary, it was found that the levels of TRf were
affected by the profession (t = 2.51, p = 0.01) and mar-
riage (t = 2.17, p = 0.03), C3 levels were influenced by the
age (t = 2.37, p = 0.02) and smoking (t = 2.12, p = 0.04).
Association between acute-phase response proteins and
perimenopausal depression
The results of TRf (t-test, t = −0.534, df = 63, p = 0.595)
AAT (t-test, t = −1.531, df = 63, p = 0.131) HP (t-test, t =
0.105, df = 63, p = 0.917) and C3 (t-test, t = 0.031, df = 63,
p = 0.976) for individual cases of perimenopausal women,
with or without depression, are shown in Table 2, whereas
the results for C4 (Mann–Whitney U, Z = −0.763, p =
0.445) and CRP (Mann–Whitney U, Z = −0.521, p = 0.603)
are depicted in Table 3. The concentration of acute-phase
response proteins of women with depression did not differ
significantly from those of normal controls.
The effect of SSRIs on acute-phase response protein
concentration
It was examined whether the depressed women, who were
taking SSRIs, had different levels of acute-phase response
proteins compared to depressed women, who were not
taking SSRIs, and to women of normal controls. TheTable 5 Serum C4 and CRP concentrations in 39 women with p
(n = 17) or not (n = 22) selective serotonin reuptake inhibitors (
depression (n = 26)
Perimenopausal with Women depressio
Not treated with SSRIs Treated with SSRIs
N = 22 N = 17
C4 (mg/dl) 37.68 (17.97-47.86) 33.75 (23.26-47.86)
CRP (mg/dl) 0.23 (0.00-0.64) 0.26 (0.00-0.76)
The results of C4 and CRP are expressed as medians (10-90%); ns, not significant.results demonstrated that the levels of TRf (ANOVA F =
0.718, p = 0.492), AAT (ANOVA F = 2.365, p = 0.102), HP
(ANOVA F = 0.085, p = 0.918) and C3 (ANOVA F = 1.685,
p = 0.194) did not differ between the three groups (one-
way ANOVA, Table 4). The same result was found for C4
(Kruskal-Wallis chi-square = 3.119, df = 2, p = 0.210) and
CRP (Kruskal-Wallis, chi-square = 0.624, df = 2, p = 0.732)
(Kruskal-Wallis, Table 5).
Hormone levels and cycle irregularity in relation to the
presence of a first- ever depressive episode in
perimenopause
It was studied whether women, who had their first-ever
episode of depression in perimenopause differed as to
their hormonal levels and months of amenorrhoea from
depressed perimenopausal women, who had a history of
depression, and from women of normal controls. The re-
sults showed that there were no differences in the levels
of FSH (one-way ANOVA, F = 2.175, p = 0.12), of E2
(Kruskal-Wallis, χ2 = 0.288, p = 0.866) and months of
amenorrhoea (Kruskal-Wallis, χ2 = 2.038, p = 0.361) be-
tween the three groups. On the contrary, depressed
women with a history of depression had lower levels of
LH (one-way ANOVA, F = 5.272, p = 0.007) (Table 6).
Relationship between reproductive hormones and
acute-phase response proteins
It was investigated whether reproductive hormones af-
fected the levels of acute-phase response proteins. Theerimenopausal depression, subdivided to those receiving





29.20 (19.06-47.14) 0.210 ns
0.10 (0.00-0.99) 0.732 ns
Table 6 Serum FSH, LH, E2 and months of amenorrhoea in women with the first episode of depression in perimenopause,
in women with history of depression and in normal controls
Controls History of depression First episode depression p
FSH 74.90 (30.11)a 63.16 (29.63)a 84.02 (30.66)a 0.12 (ANOVA)
LH 36.89 (18.49)a 27 (11.23)a 37.20 (11)a 0.007 (ANOVA)
E2 10.15 (19.2-37.84)b 8.47 (3.7-61.71)b 9.54 (2.33-49.77)b 0.866 (K-W)
Months of amenorrhoea 7 (3–12)b 4 (1–12)b 11 (1–12)b 0.361 (K-W)
aMean(SD).
bMedian (10-90%).
K-W: Kruskal-Wallis. Bold means statistical significance.
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cant correlation (Spearman’s correlation) between CRP,
TRf, HPT, C3, C4, AAT and FSH, LH and E2 in the whole
population (Table 6). This lack of a statistically significant
correlation was also observed in depressed perimeno-
pausal women, who were taking SSRIs (Table 7). On the
contrary, there was a positive correlation between HPT
and E2 (r = 0.480, p = 0.024, Table 8, Figure 1) in depressed
perimenopausal women, who were not taking SSRIs.
Discussion
The main findings of this study in Caucasian women is
that the positive acute-phase response proteins AAT, HP,
CRP, C3 and C4 are not significantly increased and the
negative acute-phase response protein TRf is not notably
decreased in perimenopausal depression. Moreover, there
is a positive correlation between HP and E2 in perimeno-
pausal women with depression, who are not taking SSRIs.
This finding does not add strength to the inflammatory
theory of depression, which supports the view that posi-
tive acute-phase response proteins are increased and nega-
tive acute-phase response proteins are decreased in major
depression.
The findings that stressors may be able to activate the
release of pro-inflammatory cytokines and an acute-
phase response in the absence of an immune challenge
further support the notion that the immune system may
be recruited to participate in the behavioural response to
stress and therefore may contribute to the biochemical
and molecular biological changes that characterize de-
pression. It is thought that the acute-phase response inTable 7 Relationship between CRP, TRf, HP, C3, C4, AAT
and FSH, LH and E2 in the whole population (Spearman’s
correlations)
C3 HP C4 CRP AAT
FSH r = −0.116 r = 0.056 r = −0.048 r = 0.045 r = 0.080
p = 0.358 p = 0.658 p = 0.701 p = 0.721 p = 0.524
LH r = −0.018 r = −0.066 r = −0.027 r = 0.025 r = −0.040
p = 0.886 p = 0.602 p = 0.829 p = 0.843 p = 0.749
E2 r = 0.071 r = −0.064 r = 0.015 r = −0.164 r = −0.179
p = 0.577 p = 0.615 p = 0.903 p = 0.196 p = 0.158patients with major depression is related to increased
production of pro-inflammatory cytokines, such as IL-1
and IL-6. IL-1 and IL-6 are pleiotropic cytokines, which
are known to be major modulators of the acute-phase
response and which may increase the synthesis of posi-
tive acute-phase proteins, while decreasing that of
negative acute-phase proteins [20]. Nevertheless, in a
previous study of ours with the same sample of the
present study, it was found that in perimenopausal de-
pression the concentration of pro-inflammatory cyto-
kines is not increased [38]. This is in accordance with
the present study, which shows that positive acute-phase
response proteins do not also increase in this type of de-
pression. However, the study of Ushiroyama et al. [39]
measured IL-6 in a large sample of non-Caucasian pa-
tients and found increased plasma levels of IL-6 in the
subgroup of women with depression and hot flashes,
when compared to women with hot flashes without de-
pression and to control subjects.
With regard to the reproductive hormone levels, it
was found that women with a history of depression had
lower levels of LH in comparison to women, who had
their first-ever depressive episode in perimenopause.
This finding is in accordance with a previous study,
which supported that women with first-onset depressive
episode during perimenopause had increased levels of
LH [32].
Our study also showed a positive correlation between
HP and E2 in depressed women, who were not taking
SSRIs. There is a lot of conversation about the effects of
estrogens on inflammation, neurodegeneration and mentalTable 8 Relationship between CRP, TRf, HP, C3, C4, AAT
and FSH, LH and E2 in depressed perimenopausal women
who were taking SSRIs (Spearman’s correlations)
C3 HP C4 CRP AAT
FSH r = −0.057 r = 0.285 r = 0.283 r = −0.213 r = 0.057
p = 0.823 p = 0.251 p = 0.255 p = 0.397 p = 0.823
LH r = −0.049 r = 0.258 r = 0.112 r = 0.198 r = 0.003
p = 0.848 p = 0.301 p = 0.660 p = 0.431 p = 0.990
E2 r = 0.015 r = −0.310 r = 0.060 r = 0.236 r = −0.178
p = 0.951 p = 0.211 p = 0.813 p = 0.346 p = 0.480
Figure 1 There is a positive correlation between haptoglobin (HPT) and E2 in perimenopausal women with depression who were not
taking SSRIs.
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of estrogens contributed to the protection of neurons
against degeneration, until the publication of the results of
Women’s Health Initiative Memory Study (WHIMS)
[40,41]. WHIMS indicated that women who received hor-
mone therapy had a two-fold greater risk of developing
Alzheimer’s disease than women in the placebo arm of the
randomised double-blind clinical trial. Analyses of the
estrogen-only therapy arm of the WHIMS trial indicated
that women, who received conjugated equine estrogens,
were not statistically different from women in the placebo
arm of the trial, but there was a trend towards greater risk
of Alzheimer’s disease and mild cognitive impairment.
Brinton [42] gave an explanation for these contra-
dictory effects of estrogens on neurodegeneration. He
claimed that the effects of estrogens depend on the
health status of neurons. In the WHIMS cohort of women
aged 65 and over with no indicators of neurological dis-
ease but with variable health status, who have been taking
estrogen and hormone therapy for 5 years, presented an
increase in the risk of developing Alzheimer’s disease.
These data would suggest that as the continuum of neuro-
logical health progresses from healthy to unhealthy, the
benefits of estrogen therapy are reversed and the estrogen
therapy leads to the neural cell damage. If neurons are
healthy at the time of estrogen exposure, their response to
estrogen is beneficial for both neurological function and
survival. On the contrary, if neurological health is com-
promised, estrogen exposure over time exacerbates neuro-
logical demise.This theory seems to give an explanation for our result
of the positive correlation between HP and E2 in de-
pressed perimenopausal women, who were not taking
SSRIs. Depression causes neurodegeneration and is asso-
ciated with cognitive decline and memory problems,
which in severe cases of major depression take the form of
pseudodementia. This neurodegeneration of depression is
mediated through inflammation. According to Brinton, in
case of depression, when neurological health is compro-
mised, estrogen exacerbates neurological demise.
Notwithstanding, the positive association between HP
and E2 was not present in depressed women who were
taking SSRIs. An explanation for this might be the fact
that SSRIs have neuroprotective effects and therefore the
neurons of these women are not so degenerated like the
neurons of depressed women, who were not treated with
SSRIs. One of the most widely used SSRI is fluoxetine.
Several lines of evidence have shown that fluoxetine pos-
sesses potent neuroprotection against hypoxic-ischemia
brain injury in rat pups [43], 3-4-methylenedioxymetham-
phetamine-induced neurotoxicity of the serotonin trans-
porter in rat brains [44] and kainic acid-induced neuronal
death in the mouse hippocampus [45]. Moreover, fluoxet-
ine has been found to modulate neural stem cell survival
and serotoninergic differentiation through modulating
Bcl-2 expression [46] as well as to protect neurons against
microglial activation and subsequent release of multiple
pro-inflammatory and cytotoxic factors [47]. Recent
studies have indicated that fluoxetine affords robust neu-
roprotection in the post-ischemic brain through its anti-
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fect of antidepressants on the adult brain has been re-
ported to be associated with increased neurogenesis,
dendritic arborisation and synaptogenesis [49]. These ac-
tions of SSRIs are mediated through the MAP-kinase sig-
nal transduction pathway (by phosphorylation of ERK)
and by stimulating neurotrophic factors, such as the
brain-derived neurotrophic factor (BDNF) and the neuro-
protective protein Bcl-2 [50].
Erdem et al. found that melancholic major depressed
patients’ serum Hp concentrations were higher than non-
melancholic major depressed patients and healthy con-
trols. They also mentioned that there was a positive
correlation between depression severity and serum Hp
concentrations among the major depressed patients [51].
Therefore, the type and severity of depression affect the
serum concentration of acute-phase response proteins.
This finding is in conformity with our results, in a manner
that in our study the depressive symptoms of perimeno-
pausal depressed patients were not so severe (mean
HAM-D= 16.8). Generally, perimenopausal depression is
a type of a moderate depression as to severity, because de-
pressive symptoms do not fulfil the complete clinical pic-
ture of major depression, either because there are not
sufficient symptoms or they are not severe enough [52].
The present study has several limitations. First of all,
perimenopausal depression has not been identified as a
clinical entity and it is not included in the DSM-IV-TR.
This study is a preliminary report and its data should be
confirmed by studies that include larger samples of pa-
tients and controls. In addition, the diagnosis of depres-
sion was not based on a semi-structured interview but
on a clinical interview and use of HAM-D 17.
Conclusions
In conclusion, the lack of association of acute-phase pro-
teins and depressive mood mentioned in this study does
not support previous findings in patients with major de-
pression. This negative finding in perimenopausal de-
pression indicates either the absence or a more complex
nature of the interactions between acute-phase proteins,
low-grade inflammation and depression. The hormonal
profile of women is a part of this complexity, because it
seems that in perimenopause the hormonal changes are
accompanied by changes of acute-phase response pro-
teins. Particularly, in perimenopausal depression, there is
an interaction between HP and E2, only in women who
were not treated with SSRIs. The neuroprotective role of
these drugs may protect depressed women from the acti-
vation of inflammation by increased levels of estrogens.
Therefore, it seems that perimenopause is a period of a
woman’s life during which hormonal, immune and meta-
bolic changes occur and interact with each other making
women vulnerable to depression.Abbreviations
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